It was also suggested that using a CCR5 agonist, a key receptor involved in controlling the migration of monocytes/macrophages and T lymphocytes (such as MIP‐1β), in conjunction with high‐dose oral antigen, might help establish a balance of GALT cytokines during ongoing autoimmune disease, promoting an anti‐inflammatory state and reducing autoreactivity [58]. Here, CCL4 is linked to autoimmune disease.